Clinical Trial Update: P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

View source ↗

Summary

This clinical trial update evaluates whether P16 staining can serve as a prognostic biomarker for serous papillary endometrial cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Serous Papillary Endometrial Cancer

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Serous Papillary Endometrial Cancer | Status: COMPLETED